These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 19904584)

  • 1. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.
    de Winter BC; van Gelder T; Sombogaard F; Shaw LM; van Hest RM; Mathot RA
    J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):541-64. PubMed ID: 19904584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients.
    van Hest RM; van Gelder T; Vulto AG; Shaw LM; Mathot RA
    Clin Pharmacokinet; 2009; 48(7):463-76. PubMed ID: 19691368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
    Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism-based enterohepatic circulation model of mycophenolic acid and its glucuronide metabolite: assessment of impact of cyclosporine dose in Asian renal transplant patients.
    Yau WP; Vathsala A; Lou HX; Zhou S; Chan E
    J Clin Pharmacol; 2009 Jun; 49(6):684-99. PubMed ID: 19386625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.
    de Winter BC; Mathot RA; Sombogaard F; Neumann I; van Hest RM; Doorduijn JK; van Gelder T
    Ther Drug Monit; 2010 Oct; 32(5):606-14. PubMed ID: 20720518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients.
    Colom H; Lloberas N; Andreu F; Caldés A; Torras J; Oppenheimer F; Sanchez-Plumed J; Gentil MA; Kuypers DR; Brunet M; Ekberg H; Grinyó JM
    Kidney Int; 2014 Jun; 85(6):1434-43. PubMed ID: 24402086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation.
    Naito T; Shinno K; Maeda T; Kagawa Y; Hashimoto H; Otsuka A; Takayama T; Ushiyama T; Suzuki K; Ozono S
    Biol Pharm Bull; 2006 Feb; 29(2):275-80. PubMed ID: 16462031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients.
    Kuypers DR; Ekberg H; Grinyó J; Nashan B; Vincenti F; Snell P; Mamelok RD; Bouw RM
    Clin Pharmacokinet; 2009; 48(5):329-41. PubMed ID: 19566116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo higher glucuronidation of mycophenolic acid in male than in female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil.
    Morissette P; Albert C; Busque S; St-Louis G; Vinet B
    Ther Drug Monit; 2001 Oct; 23(5):520-5. PubMed ID: 11591897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of mycophenolate mofetil.
    Bullingham RE; Nicholls AJ; Kamm BR
    Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies.
    Jiao Z; Zhong JY; Zhang M; Shi XJ; Yu YQ; Lu WY
    Eur J Clin Pharmacol; 2007 Jan; 63(1):27-37. PubMed ID: 17093994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of mycophenolate sodium co-administered with tacrolimus in the first year after renal transplantation.
    Sobiak J; Resztak M; Głyda M; Szczepaniak P; Chrzanowska M
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):331-8. PubMed ID: 25663618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Improved Dosing Regimens for Mycophenolate Mofetil Based on Population Pharmacokinetic Analyses in Adults with Lupus Nephritis.
    Abd Rahman AN; Tett SE; Abdul Gafor HA; McWhinney BC; Staatz CE
    Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):993-1004. PubMed ID: 28536776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients.
    Merkel U; Lindner S; Vollandt R; Sperschneider H; Balogh A
    Int J Clin Pharmacol Ther; 2005 Aug; 43(8):379-88. PubMed ID: 16119513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation.
    Mino Y; Naito T; Matsushita T; Otsuka A; Ushiyama T; Ozono S; Hishida A; Kagawa Y; Kawakami J
    Ther Drug Monit; 2008 Dec; 30(6):656-61. PubMed ID: 18978521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycophenolic Acid and Its Metabolites in Kidney Transplant Recipients: A Semimechanistic Enterohepatic Circulation Model to Improve Estimating Exposure.
    Okour M; Jacobson PA; Ahmed MA; Israni AK; Brundage RC
    J Clin Pharmacol; 2018 May; 58(5):628-639. PubMed ID: 29329489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.
    Cremers S; Schoemaker R; Scholten E; den Hartigh J; König-Quartel J; van Kan E; Paul L; de Fijter J
    Br J Clin Pharmacol; 2005 Sep; 60(3):249-56. PubMed ID: 16120063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of Free from Total Mycophenolic Acid Concentrations in Stable Renal Transplant Patients: A Population-Based Approach.
    Colom H; Andreu F; van Gelder T; Hesselink DA; de Winter BCM; Bestard O; Torras J; Cruzado JM; Grinyó JM; Lloberas N
    Clin Pharmacokinet; 2018 Jul; 57(7):877-893. PubMed ID: 29159710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients.
    Shipkova M; Armstrong VW; Weber L; Niedmann PD; Wieland E; Haley J; Tönshoff B; Oellerich M;
    Ther Drug Monit; 2002 Jun; 24(3):390-9. PubMed ID: 12021631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.